British Patient Capital
About British Patient Capital
British Patient Capital is a commercial subsidiary of the British Business Bank that provides long-term equity investment to high-growth companies across the United Kingdom. The organisation commits capital to venture and growth funds as well as making direct investments through programmes such as Future Fund Breakthrough. Recent coverage has focused on the company's participation in funding rounds for fintech and life sciences firms alongside its commitments to various venture capital funds.
FF News has published 9 stories featuring British Patient Capital since 2021, most recently "Form3 Successfully Completes $60M Series C Extension, With New Investment From British Patient Capital and Existing Shareholders" (10 September 2024).
Part of: Business Bank UK
Latest British Patient Capital news
- Form3 Successfully Completes $60M Series C Extension, With New Investment From British Patient Capital and Existing Shareholders 10 September 2024
- British Patient Capital's total investment hits 1.9 billion 27 November 2023
- British Patient Capital commits €25m to Finch Capital’s Fund III 5 October 2022
- British Patient Capital commits £30m to Crane Venture Partners’ second fund 24 May 2022
- British Patient Capital Comment on PitchBook data – Venture Capital Industry in Europe 2021 21 January 2022
- VIII British Patient Capital: 2022 Vision 18 January 2022
- British Patient Capital invests in Quell Therapeutics’ $156m funding round through Future Fund: Breakthrough 29 November 2021
- Fund: Breakthrough Now Open for Investor Applications 20 July 2021
- British Patient Capital Announces $75M Commitment to $680M Balderton Capital Growth Fund 10 June 2021